Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E8DX
|
|||
| Former ID |
DNC009640
|
|||
| Drug Name |
6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione
|
|||
| Synonyms |
CHEMBL511329; 6-Pyridin-3-yl-3,4-dihydroquinoline-2(1H)-thione; SCHEMBL1119425; BBIRVEDVKRWBOZ-UHFFFAOYSA-N; BDBM50273815; ZINC40380214; 6-pyridin-3-yl-3,4-dihydro-1H-quinoline-2-thione
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H12N2S
|
|||
| Canonical SMILES |
C1CC(=S)NC2=C1C=C(C=C2)C3=CN=CC=C3
|
|||
| InChI |
1S/C14H12N2S/c17-14-6-4-11-8-10(3-5-13(11)16-14)12-2-1-7-15-9-12/h1-3,5,7-9H,4,6H2,(H,16,17)
|
|||
| InChIKey |
BBIRVEDVKRWBOZ-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Steroid 11-beta-hydroxylase (CYP11B1) | Target Info | Inhibitor | [1] |
| Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Inhibitor | [1] | |
| BioCyc | Superpathway of steroid hormone biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Androgen biosynthesis | ||||
| Mineralocorticoid biosynthesis | ||||
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Metabolic pathways | ||||
| Ovarian steroidogenesis | ||||
| Prolactin signaling pathway | ||||
| Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
| Steroidogenesis | ||||
| Reactome | Androgen biosynthesis | |||
| Glucocorticoid biosynthesis | ||||
| Endogenous sterols | ||||
| WikiPathways | Metapathway biotransformation | |||
| Steroid Biosynthesis | ||||
| Oxidation by Cytochrome P450 | ||||
| Metabolism of steroid hormones and vitamin D | ||||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| Prostate Cancer | ||||
| Phase 1 - Functionalization of compounds | ||||
| Corticotropin-releasing hormone | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-... J Med Chem. 2008 Dec 25;51(24):8077-87. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.